00:04 , Apr 6, 2019 |  BioCentury  |  Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
02:21 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

AACR moves in a myeloid direction

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...
20:53 , Dec 14, 2018 |  BC Week In Review  |  Clinical News

SanBio’s SB623 meets in Phase II for TBI

SanBio Co. Ltd. (Tokyo:4592) reported Nov. 1 that intracranial SB623 cells met the primary endpoint of improving motor function as measured by the change from baseline in Fugl-Meyer Motor Scale (FMMS) score at 24 weeks...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
18:43 , Oct 18, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Patient sample and mouse studies suggest inhibiting Notch 1 could help treat metastatic medulloblastoma. In primary tumor samples from medulloblastoma patients, levels of Notch 1 were higher in patients with metastases than...
17:40 , Sep 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Gastrointestinal; cancer

INDICATION: Adenomatous polyps; colorectal cancer Patient sample, cell culture and mouse studies suggest inhibiting JAG1 could help treat familial adenomatous polyposis (FAP) and Notch 1-positive, MFNG-negative colorectal cancers. In Notch 1-positive tumor samples from 198...
23:05 , Jan 18, 2018 |  BC Innovations  |  Translation in Brief

A notch for tankyrase

New York University School of Medicine researchers have identified a multitude of tankyrase targets, including factors in the Notch and Wnt/β-catenin pathways, that offer new opportunities for tankyrase inhibitors in cancer. In a Nature Communications...
21:45 , Jul 13, 2017 |  BC Innovations  |  Targets & Mechanisms

Insider signaling

With evidence mounting that cell surface receptors keep signaling after they are internalized, a Takeda-backed study from Monash University has shown how the phenomenon could solve the riddle of why antagonists of the substance P...
20:18 , Jul 7, 2017 |  BC Week In Review  |  Financial News

CIRM awards $44M in grants

The California Institute for Regenerative Medicine awarded more than $44 million over four grants to develop stem cell therapies to treat stroke, a fetal blood disorder and acute myelogenous leukemia (AML). CIRM awarded $20 million...
22:22 , Jun 30, 2017 |  BC Extra  |  Financial News

CIRM awards $44M in grants

The California Institute for Regenerative Medicine awarded more than $44 million over four grants to develop stem cell therapies to treat stroke, a fetal blood disorder and acute myelogenous leukemia (AML). CIRM awarded $20 million...